Department of Urology, Nankai Hospital, Tianjin 300100, P.R. China.
Mol Med Rep. 2017 Sep;16(3):2868-2874. doi: 10.3892/mmr.2017.6908. Epub 2017 Jun 30.
Even though standard treatment options are available for prostate cancer patients, prostate cancer is still a leading cause of death in many Western countries due to drug resistance and recurrence. Immune checkpoint blockade therapy has been proved to be very effective in some melanoma patients, which might dependent on the preconditioned immune system. Here we explored the effect of chemotherapy (oxaliplatin) in combination with immune checkpoint blockade therapy (anti‑PD‑1 treatment) in prostate cancer cell lines and pre‑clinical animal models. We found that oxaliplatin is effective in castration‑resistant cells and enhanced the response of prostate cancer to anti‑PD‑1 antibody treatment. Oxaliplatin stimulated the immunogenic potential and established a pro‑immune microenvironment in prostate cancer. In conclusion, oxaliplatin sensitized anti‑PD‑1 treatment in prostate cancer and this combination may be an option for castration‑resistant prostate cancer patients.
尽管前列腺癌患者有标准的治疗选择，但由于耐药性和复发，前列腺癌仍然是许多西方国家的主要死亡原因。免疫检查点阻断疗法已被证明对一些黑色素瘤患者非常有效，这可能取决于预先存在的免疫系统。在这里，我们研究了化疗（奥沙利铂）联合免疫检查点阻断疗法（抗 PD-1 治疗）在前列腺癌细胞系和临床前动物模型中的作用。我们发现奥沙利铂在去势抵抗细胞中有效，并增强了前列腺癌对抗 PD-1 抗体治疗的反应。奥沙利铂刺激了前列腺癌的免疫原性潜力并建立了有利于免疫的微环境。总之，奥沙利铂使抗 PD-1 治疗在前列腺癌中变得敏感，这种联合治疗可能是去势抵抗性前列腺癌患者的一种选择。
